Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 3/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24481818 | 0.81 | HTR2C (0.42) | OPRM1HTR2AHTR2CKDM1AIDO1 | |
| SCHEMBL768770 | 0.79 | HTR2A (0.41) | OPRM1HTR2AHTR2CKDM1ANOS3 | |
| SCHEMBL3028639 | 0.77 | TRPM5 (0.41) | HTR2AHTR2CCHRNB2CHRNA4HTR2B | |
| SCHEMBL6583849 | 0.77 | CHRNB2 (0.34) | CHRNB2CHRNA4 | |
| SCHEMBL6989944 | 0.77 | OPRK1 (0.40) | OPRM1ACHE | |
| Hydrochloric Acid SCHEMBL3020631 | 0.76 | CHRNB2 (0.33) | KDM1ACHRNB2CHRNA4 | |
| SCHEMBL5524678 | 0.73 | HTR2A (0.45) | OPRM1HTR2AHTR2CACHEKDM1A | |
| SCHEMBL3161060 | 0.73 | OPRM1 (0.44) | OPRM1HTR2AHTR2CACHEHTR2B | |
| SCHEMBL7439467 | 0.73 | OPRM1 (0.44) | OPRM1HTR2AHTR2CACHEHTR2B | |
| SCHEMBL8976654 | 0.71 | HTR2C (0.42) | OPRM1HTR2AHTR2CACHEKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600299-B1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3504185-B1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3504185-B1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3585774-B1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3585774-B1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11034661-B2 | Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034661-B2 | Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10988487-B2 | Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988487-B2 | Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10927086-B2 | Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3600299-A1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3504185-A1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018183097-A1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018156443-A1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018044663-A1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018044663-A1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | WO | disclosed |
| EP-0940386-B1 | Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-05-22 | — | — | EP | disclosed |
| US-6107345-A | ANTIDEPRESSANT; PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 2000-08-22 | — | — | US | disclosed |
| EP-0940386-A1 | Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-09-08 | — | — | EP | disclosed |
| US-4567181-A | Bicyclo (4.2.0) 1,3,5-octatriene compounds and use as α-adrenergics | ADIR, S.A.R.L. (FR) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927086-B2 | Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, KYNU | OPRM1 2810/4885HTR2A 237/4885HTR2C 377/4885 |
| US-10988487-B2 | Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | OPRM1 2266/4885HTR2A 198/4885HTR2C 281/4885 |
| US-11034661-B2 | Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors | IDO1, IDO2, INMT | OPRM1 2204/4885HTR2A 219/4885HTR2C 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.